DOCSLIB.ORG

Microscopic Polyangiitis Presenting with Splenic Infarction: a Case Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Microscopic Polyangiitis Presenting with Splenic Infarction: a Case Report medicina Case Report Microscopic Polyangiitis Presenting with Splenic Infarction: A Case Report Sang Wan Chung Division of Rheumatology, Department of Internal Medicine, School of Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea; [email protected]; Tel.: +82-2-958-8200 Abstract: Microscopic polyangiitis (MPA) is an anti-neutrophil cytoplasmic antibody (ANCA)- associated vasculitis (AAV). The splenic involvement in AAV is known to be rare, and that in MPA has not been reported to date. A 74-year-old woman was admitted owing to left arm numbness and weakness. The patient was diagnosed as MPA with vasculitic neuropathy. Her abdominal computed tomography (CT) revealed splenic infarction incidentally. The splenic infarction had been resolved at follow-up CT after treatment. If splenic involvement of MPA was not considered, treatment may have been delayed in order to differentiate other diseases. Herein, I report the first case of splenic involvement of MPA. Keywords: ANCA-associated vasculitis; splenic infarction; MPA 1. Introduction Microscopic polyangiitis (MPA) is a type of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) that predominantly affects small-sized vessels. The most commonly affected organs are the kidney and lung. Necrotizing and crescentic Citation: Chung, S.W. Microscopic glomerulonephritis and diffuse alveolar hemorrhage are the main clinical presentations. Polyangiitis Presenting with Splenic General signs such as fever, weight loss, peripheral neuropathy, cutaneous manifestations, Infarction: A Case Report. Medicina and upper respiratory tract involvement may be present [1]. In AAV numerous atypical 2021, 57, 157. https://doi.org/ manifestations may also occur, among which, though rarely reported, is splenic involve- 10.3390/medicina57020157 ment, particularly in patients with granulomatous polyangiitis (GPA) [2]. In MPA, splenic involvement has been reported very rarely. Herein, I report a case of splenic involvement Academic Editor: Emanuel of MPA. Della-Torre Received: 14 December 2020 2. Case Presentation Accepted: 5 February 2021 Published: 9 February 2021 A 74-year-old female patient presented to the emergency department of Kyung Hee University Medical Center because of dizziness and generalized weakness that started Publisher’s Note: MDPI stays neutral 2 days prior. The patient had a history of old cerebral infarction and was taking oral medica- with regard to jurisdictional claims in tions for hypertension and dyslipidemia. Brain magnetic resonance imaging (MRI) revealed published maps and institutional affil- an acute focal infarction in the right basal ganglia. At that time, in the laboratory examina- iations. tions, the erythrocyte sedimentation rate (ESR) was 74 mm/h (normal range, <20 mm/h) and C-reactive protein (CRP) level was 6.61 mg/dL (<0.5 mg/dL) Aspirin was prescribed to the patient. One month later, the patient was admitted to our neurology clinic because of weakness in her left arm and numbness in both hands. MRI revealed no diffusion-restricted lesion in the brain. Physical examination revealed no remarkable findings except for pares- Copyright: © 2021 by the author. Licensee MDPI, Basel, Switzerland. thesia in the left hand. The patient’s motor power of four limbs were normal (grade 5). This article is an open access article Her initial chest radiograph was normal. Her laboratory examination results showed a distributed under the terms and white blood cell count of 9.79 × 109/L (76% neutrophils), ESR of 120 mm/h, and CRP conditions of the Creative Commons level of 18.44 mg/dL. However, she had no fever. Her serum creatinine level (0.92 mg/dL) 2 Attribution (CC BY) license (https:// and estimated glomerular filtration rate (GFR; 63.59 mL/min per 1.73 m ) were within creativecommons.org/licenses/by/ the normal ranges. No proteinuria was identified. Chest computed tomography (CT) 4.0/). and abdominal CT were performed to exclude hidden malignancy. Chest CT revealed a Medicina 2021, 57, 157. https://doi.org/10.3390/medicina57020157 https://www.mdpi.com/journal/medicina Medicina2021, 57, x FOR PEER REVIEW 2 of 4 1.73 m2) were within the normal ranges. No proteinuria was identified. Chest computed Medicina 2021, 57, 157 tomography (CT) and abdominal CT were performed to exclude hidden malignancy. 2 of 4 Chest CT revealed a subpleural nodule measuring approximately 1.5 cm in the right lower lobe. Abdominal CT revealed multiple small ill-defined low-attenuated lesions in the spleensubpleural nodules (Figure nodule 1). measuring Her thrombophilia approximately screening 1.5 cm test in the result right was lower negative. lobe. Abdominal The CT Padua predictionrevealed score multiple was small 2, in ill-defined the low risk.Her low-attenuated echocardiography lesions in the was spleen normal nodules and (Figure1). 24-hour HolterHer thrombophilia monitoring revealed screening normal test result sinus was rhythm. negative. Nerve The Padua conduction prediction tests score re- was 2, in vealed sensorimotorthe low risk.Her polyneuropathy. echocardiography The myeloperoxidase was normal and 24-hour(MPO)-ANCA Holter monitoringtest result revealed was positivenormal (5.10 sinus index). rhythm. Percutaneous Nerve conduction needle biopsy tests revealed of the sensorimotorpulmonary nodule polyneuropathy. was The performedmyeloperoxidase first; however, the (MPO)-ANCA pathological testresults result showed was positive only focal (5.10 acute index). inflammatory Percutaneous needle cell infiltration,biopsy with of the no pulmonary evidence of nodule malignancy. was performed The second first; biopsy however, of the the sural pathological nerve results demonstratedshowed perivascular only focal inflammatory acute inflammatory cell infiltration cell infiltration, and withnecrotizing no evidence vasculitis. of malignancy. These findingsThe second were biopsyconsistent of the with sural vascul nerveitic demonstrated peripheral neuropathy. perivascular inflammatoryBy considering cell infiltra- the resultstion of the and MPO-ANCA necrotizing vasculitis. test and the These pathological findings were profile consistent of the sural with vasculiticnerve, the peripheral patient wasneuropathy. diagnosed By as considering having MPA-associat the results ofed theneuropathy MPO-ANCA with test a splenic and the infarction pathological profile and pulmonaryof the suralinflammatory nerve, the nodule. patient wasShe diagnosedreceived steroid as having pulse MPA-associated therapy (methylpred- neuropathy with a nisolone, 125splenic mg/day infarction for 3 and days) pulmonary on day 20 inflammatory of hospitalization, nodule. followed She received by steroidcyclophos- pulse therapy phamide (500(methylprednisolone, mg/m2every 4 weeks 125 for mg/day six doses) for 3with days) steroid on day maintenance 20 of hospitalization, therapy. She followed by showed improvementcyclophosphamide after the (500 steroid mg/m therap2 everyy. Her 4 weeks ESR level for sixdecreased doses) withto 49 steroidmm/h and maintenance the CRP leveltherapy. decreased She showed to 0.5 mg/dL. improvement The peripheral after the numbness steroid therapy. subsided Her slowly. ESR levelAfter decreased 1 month, theto 49patient’s mm/h pancreatic and the CRP enzyme level levels decreased (amylase, to 0.5 192 mg/dL. U/L (23–85 The peripheral U/L) and lipase numbness sub- 346 U/L (0–160sided slowly.U/L)) were After elevated 1 month, without the patient’s abdominal pancreatic pain. Abdominal enzyme levels CT (amylase,was per- 192 U/L formed to(23–85 evaluate U/L) for andpancreatitis lipase 346 and U/L reve (0–160aled improvement U/L)) were of elevated the splenic without lesion abdominal such pain. as the infarction.Abdominal The CT patient was performed had an uneventful to evaluate course for pancreatitis for 5 months and revealedafter the improvementtreat- of ment.Thisthe study splenic was lesion approved such asby the the infarction. Institutional The Review patient hadBoard an uneventful(IRB) of Kyung course Hee for 5 months Medical Center,after the treatment.Thisand the requirement study was for approved informed by theconsent Institutional was waived Review Board(IRB (IRB) of 2020-12-083).Kyung Hee Medical Center, and the requirement for informed consent was waived (IRB 2020-12-083). (A) Figure 1. Cont. Medicina2021, 57, x FOR PEER REVIEW 3 of 4 Medicina 2021, 57, 157 3 of 4 (B) Figure 1. AbdominalFigure 1. Abdominal computed computedtomography tomography (CT) image. (CT) (A) image.Axial CT (A image) Axial on CT day image 1, illustrating on day 1, illustrating wedge-shapedwedge-shaped splenic infarcts splenic (white infarcts arrow). (white (B) Axial arrow). CT image (B) Axial 2 months CT image later, 2showing months an later, im- showing an proved splenicimproved infarction. splenic infarction. 3. Discussion3. Discussion MPA is oneMPA of isthe one main of thesubgroups main subgroups of AAV. AAV of AAV. is a AAV group is of a groupsystemic of systemicvasculitis vasculitis characterizedcharacterized by inflammation by inflammation of small- of to small- medium-sized to medium-sized vessels. vessels. AAV can AAV be can divided be divided into into threethree entities, entities, namely namely MPA, MPA, GPA, GPA, and and eosinophilic eosinophilic GPA, GPA, according according to to histological histological findings findings andand clinical manifestationsmanifestations [3[3,4].,4]. Its Its histology histology is is characterized characterized by by necrotizing necrotizing small vessel small vesselvasculitis
Load more

Recommended publications
  • WO 2017/048702 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2017/048702 A l 2 3 March 2017 (23.03.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 487/04 (2006.01) A61P 35/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/519 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 16/05 1490 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 13 September 2016 (13.09.201 6) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/218,493 14 September 2015 (14.09.2015) US (84) Designated States (unless otherwise indicated, for every 62/218,486 14 September 2015 (14.09.2015) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: INFINITY PHARMACEUTICALS, INC.
    [Show full text]
  • Pulmonary Microscopic Polyangiitis Presenting As Acute Respiratory Failure from Diffuse Alveolar Hemorrhage
    Case report SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2015; 32; 372-377 © Mattioli 1885 Pulmonary microscopic polyangiitis presenting as acute respiratory failure from diffuse alveolar hemorrhage Katharine K. Roberts1, Michael M. Chamberlin2, Allen R. Holmes3, Jonathan L. Henderson4, Robert L. Hutton3, William N. Hannah1, Michael J. Morris4 1 Internal Medicine Residency, Department of Medicine, San Antonio Military Medical Center; 2 Internal Medicine, United States Army Health Clinic, Vilseck, Germany; 3 Pathology Residency, Department of Pathology, San Antonio Military Medical Center; 4 Pulmonary/ Critical Care Service, Department of Medicine, San Antonio Military Medical Center Abstract. MicrMicroscopicoscopic polyangiitis and granulomatosis with polyangiitis are rare anti-neutrophilic cytoplas-cytoplas- mic antibody-associated systemic vasculitides that predominantly affect small to medium sized vessels of the lungs and kidneys. These syndromes are largely confined to older adults and often present sub-acutely follow- ing weeks to months of nonspecific prodromal symptoms. While both diseases often manifest within multiple organ systems concurrently, the disease spectrum of microscopic polyangiitis almost always includes the kidneys, while granulomatosis with polyangiitis is most commonly associated with pulmonary disease. We present two cases of rapid onset respiratory failure secondary to diffuse alveolar hemorrhage in young active duty military personnel. After serological testing and surgical lung biopsy, both patients were
    [Show full text]
  • ANCA--Associated Small-Vessel Vasculitis
    ANCA–Associated Small-Vessel Vasculitis ISHAK A. MANSI, M.D., PH.D., ADRIANA OPRAN, M.D., and FRED ROSNER, M.D. Mount Sinai Services at Queens Hospital Center, Jamaica, New York and the Mount Sinai School of Medicine, New York, New York Antineutrophil cytoplasmic antibodies (ANCA)–associated vasculitis is the most common primary sys- temic small-vessel vasculitis to occur in adults. Although the etiology is not always known, the inci- dence of vasculitis is increasing, and the diagnosis and management of patients may be challenging because of its relative infrequency, changing nomenclature, and variability of clinical expression. Advances in clinical management have been achieved during the past few years, and many ongoing studies are pending. Vasculitis may affect the large, medium, or small blood vessels. Small-vessel vas- culitis may be further classified as ANCA-associated or non-ANCA–associated vasculitis. ANCA–asso- ciated small-vessel vasculitis includes microscopic polyangiitis, Wegener’s granulomatosis, Churg- Strauss syndrome, and drug-induced vasculitis. Better definition criteria and advancement in the technologies make these diagnoses increasingly common. Features that may aid in defining the spe- cific type of vasculitic disorder include the type of organ involvement, presence and type of ANCA (myeloperoxidase–ANCA or proteinase 3–ANCA), presence of serum cryoglobulins, and the presence of evidence for granulomatous inflammation. Family physicians should be familiar with this group of vasculitic disorders to reach a prompt diagnosis and initiate treatment to prevent end-organ dam- age. Treatment usually includes corticosteroid and immunosuppressive therapy. (Am Fam Physician 2002;65:1615-20. Copyright© 2002 American Academy of Family Physicians.) asculitis is a process caused These antibodies can be detected with indi- by inflammation of blood rect immunofluorescence microscopy.
    [Show full text]
  • (Mabthera) Maintenance Therapy for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) NIHRIO (HSRIC) ID: 12979 NICE ID: 9284
    NIHR Innovation Observatory Evidence Briefing: August 2017 Rituximab (MabThera) maintenance therapy for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) NIHRIO (HSRIC) ID: 12979 NICE ID: 9284 LAY SUMMARY Anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis is a rare condition in which abnormal antibodies attack the body’s own cells, causing inflammation. Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are two different types of ANCA-associated vasculitis. These conditions can cause serious organ damage and severely impact quality of life. Following initial treatment, these conditions frequently return. Rituximab is a medicine, delivered as an infusion into the vein. It destroys B cells, the part of the immune system thought to be involved in this type of vasculitis. It is already licensed for use (and recommended by NICE) as a treatment for people with GPA or MPA. There has however not been sufficient evidence to consider the continued use of rituximab as maintenance therapy, although this is already commissioned by NHS England in some instances. The current clinical trial examines the use of rituximab as a maintenance treatment in patients with GPA or MPA. If licensed, rituximab would offer another option for maintenance therapy in this patient cohort. This briefing is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes or commissioning without additional information. This briefing presents independent research funded by the National Institute for Health Research (NIHR).
    [Show full text]
  • Case Report Spontaneous Rupture of Kidneys Triggered by Microscopic Polyangiitis
    Int J Clin Exp Med 2019;12(3):2883-2887 www.ijcem.com /ISSN:1940-5901/IJCEM0085468 Case Report Spontaneous rupture of kidneys triggered by microscopic polyangiitis Man-Yu Zhang1,2*, Ding-Ping Yang3*, Jun-Ke Zhou2*, Xue-Yan Yang2*, Jun-Yun Liu2, Ding-Wei Yang1 1Department of Nephrology, Tianjin Hospital, Tianjin 300211, China; 2Tianjin Medical University, Tianjin 300070, China; 3Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China. *Equal contributors. Received April 17, 2018; Accepted February 12, 2019; Epub March 15, 2019; Published March 30, 2019 Abstract: Rationale: Microscopic polyangiitis (MPA) is defined by the 2012 revised Chapel Hill Consensus Confer- ence Nomenclature of Vasculitides as necrotizing vasculitis, with few or no immune deposits, predominantly affect- ing small vessels (i.e. capillaries, venules, or arterioles) and granulomatous inflammation is absent. MPA is clinically characterized by small-vessel vasculitis primarily affecting the kidneys and lungs but other organs may be involved as well. Spontaneous rupture of kidneys is a rare but extremely dangerous event in clinical practice. Here is reported a successfully treated case of spontaneous renal rupture triggered by MPA. Patient concerns: A 57-year-old female complaining of fever for 2 weeks and edema for 1 week presented with newly developed severe lumbago, delirium, acute renal failure, and hemorrhagic shock. Radiological imaging revealed large bilateral peri-renal hematoma and compression of renal parenchyma. Diagnoses: Acute renal failure and hemorrhagic shock caused by spontaneous rupture of kidneys which was triggered in turn due to MPA. Interventions: Measures of absolute bed rest, blood transfusion, hemostasis, and rehydration were immediately taken as first aid measure to stabilize vital signs.
    [Show full text]
  • Microscopic Polyangiitis1
    Microscopic polyangiitis1 Author: Professor J. Charles Jennette2 Creation Date: October 2002 Scientific Editor: Professor Loïc Guillevin 1This text was adapted from: Jennette JC, Thomas DB, Falk RJ. Microscopic polyangiitis (microscopic polyarteritis). Semin Diagn Pathol. 2001;18:3-13. 2Department of Pathology and Laboratory Medicine, University of North Carolina, 303 Brinkhous-Bullitt Building, NC 27599-7525 Chapel Hill, United States. [email protected] Abstract Keywords Disease name Definition Differential diagnosis Frequency Clinical manifestation Diagnostic methods Treatment Unresolved questions References Abstract Microscopic polyangiitis (MPA) refers to a necrotizing systemic vasculitis with few or no immune deposits that affects small vessels (ie, capillaries, venules and arterioles). Arteries, especially small arteries, are often but not always involved. Vessels of any type in any organ can be affected, resulting in a wide variety of signs and symptoms, and nonspecific clinical manifestations. Common signs and symptoms include nephritis, pulmonary hemorrhage, purpura, peripheral neuropathy, abdominal pain, myalgias and arthralgias. MPA is the most common antineutrophil cytoplasmic autoantibodies (ANCA)-associated small-vessel vasculitis. Most patients have positive myeloperoxidase MPOANCA (PANCA), although proteinase 3 PR3 ANCA (CANCA) may be also present. MPA has an incidence of approximately 1:100,000 with a slight predominance in men, and a mean age of onset of about 50 years. Treatment of patients with MPA consists of three
    [Show full text]
  • The Importance of Microscopic Polyangiitis in Differential Diagnosis of Hemoptysis
    Case Report Acta Medica Anatolia Volume 1 Issue 1 2013 The Importance of Microscopic Polyangiitis in Differential Diagnosis of Hemoptysis 1 2 3 4 Fatih Demircan , Faruk Kilinc , Nevzat Gözel , Cemil Göya 1 Department of Internal Medicine, Private Cagri Medical Center, Elazig, Turkey 2 Department of Internal Medicine, Dicle University Faculty of Medicine, Diyarbakir, Turkey 3 Department of Internal Medicine, Private Cagrı Dialysis Center, Elazig, Turkey 4 Department of Radiology, Dicle University Faculty of Medicine, Diyarbakir, Turkey Abstract Microscopic polyangiitis (MPA) is non-granulomatous necrotizing vasculitis, which affect small vessels of kidney, skin and lung. This disease is characterized by the absence of immune deposits and positive ANCA in biopsy. In this article, we describe a microscopic polyangiitis case that presenting with hemoptysis, dyspnea and progressive cough and emphasized that if a patient with nonspesific pulmonary symptoms, we should consider in the differential diagnosis of vasculitis. Keywords: Microscopic polyangiitis, hemoptysis, vasculitis Received: 14.10.2013 Accepted: 10.12.2013 Introduction Microscopic Polyangiitis (MPA) is a type of systemic MPA has an onset with flu-like non-specific symptoms necrotizing vasculitis manifesting with inflammation and the mean age of onset is 57 with a mildly higher that involves the kidneys, skin and the lungs. This incidence among males compared to females. disease involving the small vessels such as capillaries, Histological investigations reveal leukocytoclastic venules or arterioles is characterized by ANCA positivity vasculitis involving the small veins (1). Absence of the and absence of immune deposits on biopsy (1). granuloma form and a negative immunofluorescent (IF) detected represent significant characteristic findings In 1948, Davson et al first described cases manifesting for the disease (1, 6).
    [Show full text]
  • Microscopic Polyangiitis Associated with Primary Biliary Cirrhosis
    Case Report Microscopic Polyangiitis Associated with Primary Biliary Cirrhosis FLORENZO IANNONE, PAOLA FALAPPONE, GIOVANNI PANNARALE, ANTONIETTA GENTILE, VITO GRATTAGLIANO, MICHELE COVELLI, and GIOVANNI LAPADULA ABSTRACT. We describe a patient with microscopic polyangiitis and primary biliary cirrhosis (PBC) who presented with a non-erosive polyarthritis followed by pulmonary and renal involvement and signs of liver disorder. Detection of pANCA and antimitochondrial antibodies with results of renal and liver biopsies allowed a diagnosis of microscopic polyangiitis and PBC. To our knowledge, this is the first report of an association between the 2 diseases. (J Rheumatol 2003;30:2710–2) Key Indexing Terms: VASCULITIS GLOMERULONEPHRITIS BILIARY CIRRHOSIS Primary biliary cirrhosis (PBC) is a hepatic disease with a the second left toe were present, while rales were audible on auscultation. probable autoimmmune pathogenesis, which involves intra- ESR was raised at 102 mm/h, with CRP 5 mg/dl (normal < 1); a polyclonal hepatic bile ductules. It is frequently associated with other hypergammaglobulinemia (28%) with increased concentrations of IgG, IgA, and IgM was also present. Her γGT was 54 (normal 11-49) while other diseases such as Sjögren’s syndrome, rheumatoid arthritis, routine tests (complete blood count, liver and renal function tests) were and scleroderma1, with symptoms that usually occur before unremarkable. Rheumatoid factor (latex test) was 92 (normal < 40), anti- the clinical and/or laboratory onset of PBC. Association of nuclear antibodies were normal: speckled nuclear pattern and cytoplasmic vasculitis and PBC has seldom been reported. We describe a fluorescence 1/160 with indirect immunofluorescence (normal < 1/40). woman with microscopic polyangiitis, with kidney and lung Perinuclear antineutrophilic cytoplasm antibodies (p-ANCA; immunofluo- rescence 1/80, normal < 1/10; ELISA: anti-antimyeloperoxidase antibodies involvement, with biopsy proven PBC.
    [Show full text]
  • Vasculitis Factsheet Dr Laurence Knott Dr David Kluth
    Author Peer Reviewer Vasculitis Factsheet Dr Laurence Knott Dr David Kluth This is a leaflet for people who want general information about vasculitis. Vasculitis is a medical term meaning inflammation of blood vessels. It can be primary (occurring on its own) or secondary (occurring as part of another condition). Some people with vasculitis test positive for antibodies to constituents of certain white blood cells (anti-neutrophil cytoplasmic antibodies or ANCA) and are said to have ANCA vasculitis. Who gets vasculitis? Vasculitis is an uncommon illness. About 20 in every 100,000 people get ANCA vasculitis every year in the UK. Vasculitis can affect all age groups. Some are mostly diseases of childhood (e.g. Kawasaki), whilst others persist throughout adult life (ANCA systemic vasculitis). Some principally affect the elderly (e.g. giant cell arteritis). What causes vasculitis? In most cases the cause is not known. Many experts think that the illness is the result of infection in people who were born with a certain genetic predisposition. Vasculitis can also be caused by illnesses which trigger inflammation in the body such as rheumatoid arthritis and inflammatory diseases of the bowel. Medicines associated with vasculitis include certain types of antibiotics (e.g. quinolones, sulphonamides,beta-lactams), a nti-inflammatories, the contraceptive pill, some types of fluid tablets (thiazides) and flu vaccines. Rare types of cancer (paraproteinaemia, lymphoproliferative disorder) can occasionally cause vasculitis. Are there different types of vasculitis? There are many different types of vasculitis and various ways of classifying them. Vasculitis occurring in one part of the body is known as localised vasculitis.
    [Show full text]
  • Giant Cell Arteritis
    GIANT CELL ARTERITIS What is giant cell arteritis (GCA)? Giant cell arteritis (GCA) is a form of vasculitis—a family of rare disorders characterized by inflammation of the blood vessels, which can restrict blood flow and damage vital organs and tissues. Also called temporal arteritis, GCA typically affects the arteries in the neck and scalp, especially the temples. It can also affect the aorta and its large branches to the head, arms and legs. GCA is the most common form of vasculitis in adults over the age of 50. The most common symptoms of GCA include persistent, throbbing headaches, tenderness of the temples and scalp, jaw pain, fever, joint pain, and vision problems. Early treatment is vital to prevent serious complications such as blindness or stroke. GCA is typically treated with high doses of corticosteroids such as prednisone, sometimes in combination with other medications that suppress the immune system. Prompt treatment usually relieves symptoms, however GCA is a chronic condition with periods of relapse and remission, so ongoing medical care is usually necessary. Patients with GCA may also have symptoms of polymyalgia rheumatica (PMR), a closely related inflammatory disorder. Causes The cause of GCA is not yet fully understood by researchers. Vasculitis is classified as an autoimmune disorder—a disease which occurs when the body’s natural defense system mistakenly attacks healthy tissues. Researchers believe a combination of factors may trigger the inflammatory process. Studies have linked genetic factors, infectious agents, and a prior history of cardiovascular disease to the development of GCA. Who gets GCA? GCA is the most common form of vasculitis in older adults, affecting people over 50 years of age, with an average onset of 74 years of age.
    [Show full text]
  • Pulmonary Renal Syndrome: Update Article
    International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Review Article Pulmonary Renal Syndrome: Update Article N.S.Neki1, Satpal Aloona2 1Professor, 2Assistant Professor, Department of Medicine, Govt. Medical College/ Guru Nanak Dev Hospital, Amritsar, India- 143001 Corresponding Author: N.S. Neki Received: 08/01/2017 Revised: 24/01/2017 Accepted: 30/01/2017 ABSTRACT The pulmonary–renal syndrome (PRS) refers to the combination of diffuse alveolar haemorrhage and rapidly progressive glomerulonephritis (RPGN). Pulmonary-renal syndrome can originate from various systemic autoimmune diseases. ANCA-associated vasculitides account for approximately 60%, Goodpasture's Syndrome for approximately 20% of the cases. It is almost always autoimmune in nature, therefore steroids and other immunosupressants have role in its treatment. The underlying renal pathology is a form of focal proliferative glomerulonephritis. The lung pathology is in form of diffuse alveolar hemorrhages. Key Words: Pulmonary renal syndrome; Wegener's granulomatosis; microscopic polyangiitis; systemic lupus erythematosus. INTRODUCTION collagen. [3,4] The pulmonary-renal Pulmonary–renal syndrome (PRS) is syndrome (PRS) is a rare and life- defined as the combination of diffuse threatening condition. The clinical picture of alveolar haemorrhage (DAH) and PRS includes hemoptysis (not always glomerulonephritis. [1,2] PRS are caused by a present) due to alveolar hemorrhages, acute- wide variety of diseases, including various onset anemia and renal abnormalities forms of primary systemic vasculitis ranging from isolated urinary abnormalities (Wegener‟sgranulomatosis and microscopic to rapidly progressive glomerulonephritis. A polyangiitis), Goodpasture's syndrome significant number of patients will present which is associated with autoantibodies to with rapid clinical deterioration and require the alveolar and glomerular basement admission to the intensive care unit (ICU) membrane and systemic lupus This is attributed either to exacerbation of erythematosus.
    [Show full text]
  • Temporal Arteritis Associated with Systemic Necrotizing Vasculitis MOHAMED A
    Temporal Arteritis Associated with Systemic Necrotizing Vasculitis MOHAMED A. HAMIDOU, ANNE MOREAU, CLAIRE TOQUET, DOMINIQUE EL KOURI, PHILIPPE De FAUCAL, and JEAN-YVES GROLLEAU ABSTRACT. Objective. To evaluate the clinical and laboratory characteristics of patients with systemic vasculitis associated with temporal artery involvement. Methods. From a cohort of 120 patients fulfilling American College of Rheumatology criteria for temporal arteritis, we retrospectively identified 7 patients with systemic necrotizing vasculitis asso- ciated with histological temporal arteritis. Results. Among the 7 patients, 2 had classic polyarteritis nodosa, one had unclassified systemic vasculitis, one had Wegener’s granulomatosis (WG), and 3 had microscopic polyangiitis. The mean age of the patients was 70.2 years, and cranial symptoms revealed the disease in all but one patient. Temporal arteritis was generally associated with extracephalic manifestations suggestive of systemic vasculitis. Antineutrophilic cytoplasmic antibodies were positive in 3 of the 4 patients with small vessel vasculitis. Pathologically, the main temporal artery was involved in all but one patient, with inflammatory infiltrate of vasa vasorum and adventitia associated in 5 with small tributary involve- ment. Fibrinoid necrosis was rare, observed in 2 specimens; 2 patients with unclassified systemic vasculitis and WG had a classic giant cell arteritis (GCA) histologic pattern. Only one patient had exclusive involvement of small vessels, surrounding the spared main temporal artery. Muscle biop- sies showed histopathological evidence of vasculitis in 2 patients, skin biopsy in one, and vein biopsy in the other. Conclusion. Temporal artery involvement in systemic necrotizing vasculitis was generally associ- ated with extracranial clinical features suggestive of systemic vasculitis. Temporal artery biopsy is a simple tool for diagnosis of vasculitis, but the histopathological findings do not always discriminate between necrotizing vasculitis and classic GCA.
    [Show full text]